Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 5NIH 4NETWORK 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 4Other hematologic neoplasm 2Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1

Interventions

Azacitidine 160venetoclax 149Cytarabine 123Rituximab 94fludarabine 76Cyclophosphamide 70Imatinib Mesylate 59nilotinib 55ibrutinib 54Dasatinib 48obinutuzumab 47Bendamustine Hydrochloride 43Decitabine 39Daunorubicin 38idelalisib 31acalabrutinib 31Dexamethasone 29Chlorambucil 29Idarubicin 26gilteritinib 24Lenalidomide 23bosutinib 21asciminib 21ofatumumab 20blinatumomab 19pirtobrutinib 18fludarabine phosphate 18Vincristine 18zanubrutinib 16ublituximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Liposomes × Other hematologic neoplasm × Clear all
NCT05801835 2023-09-21

A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Phase NA Unknown
36 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00389428 2012-05-17

Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.

Jazz Pharmaceuticals

Phase 1 Completed
48 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡